Morningside Ventures Leads $53.4 Million Series B For Immune Regulation

The London and Cambridge Technology and Life Sciences teams advised Morningside Ventures on leading Immune Regulation’s Series B funding round alongside existing shareholders including London based 24Haymarket. The investment round is structured in two tranches and includes an option for Morningside to invest further capital at a step up to the initial two tranches. Immune Regulation has also raised £6 million ($7.8 million) of advance subscription funds from private investors led by Metellus AG which has been applied to the issue of shares. Total aggregate funds equal £40.6 million ($53.4 million).

The new funding will accelerate Immune Regulation’s efforts to develop first-in-class drug product candidates that reset the immune system from a pro-inflammatory state to a balanced state, with the potential to achieve long term disease remission in autoimmune and allergic diseases. 

Immune Regulation Limited is a US and UK based clinical stage biotechnology company, pioneering new technologies for regulating and resetting the immune system and developing novel first-in-class therapies for inflammatory and immunological diseases. Immune Regulation’s first-in-class immune resetting therapies, IRL201805 (‘1805) and IRL201104 (‘1104), have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system. 

The Goodwin team was led by Adam Thatcher, Sophie McGrath and Bill Schnoor. 

For additional details on the financing round, please read the press release.